Citi Sticks to Their Buy Rating for Recruit Holdings Co (RCRRF)
Confident Investing Starts Here:
In addition to Citi, Recruit Holdings Co also received a Buy from J.P. Morgan's Junko Yamamura CFA in a report issued on June 3. However, on the same day, Nomura maintained a Hold rating on Recruit Holdings Co (Other OTC: RCRRF).
Based on Recruit Holdings Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $861.78 billion and a net profit of $66.96 billion. In comparison, last year the company earned a revenue of $843.78 billion and had a net profit of $34.22 billion
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Citi Launches Real-Time Funding Capabilities for Corporate Clients in Singapore
SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Citi today announced the launch of Citi Real-Time Funding (RTF) for corporate clients in Singapore, building on its leadership in real-time liquidity solutions. Already live in Australia, Hong Kong SAR and U.K., Citi RTF enables the automated movement of funds between cross-border accounts based on pre-defined rules set by the client, helping them ensure that cash is available when and where it's needed. In the first half 2025, Citi RTF has processed more than 150 transactions across 4 clients and 3 currencies (AUD / EUR / HKD). This expansion provides Singapore-based clients with unprecedented control and flexibility over their cash, enabling instant, 24/7, cross-border liquidity transfers eliminating the need to manually transfer funds or rely on end-of-day sweeps. Our corporate clients operate in an increasingly interconnected and fast-paced global economy, where the ability to manage liquidity in real-time is paramount," said Rupa Mankad, Citi's Asia South & Singapore Head of Liquidity Management Services. "This launch of our Real-Time Funding solution in Singapore empowers businesses with continuous access to their funds, offering greater efficiency, improved working capital management and stronger control over their financial positions across borders. This is a key part of our strategy to grow our Real-Time Liquidity offering with new products and expanded reach." Citi RTF is a differentiated offering that can help corporate treasurers optimize liquidity and make funding decisions with real-time data, while also automating traditionally manual processes for 24/7 account monitoring and complex cash forecasting to support their operations. Real-Time Intercompany Transfers: Seamless and instant movement of funds between different entities within a corporate group. 24/7 Availability: Access to and deployment of liquidity around the clock, overcoming time zone limitations. Enhanced Cross-Border Capabilities: Facilitates efficient liquidity management across multiple jurisdictions without delays. This enhanced offering in Singapore underscores Citi's position as a leader in real-time liquidity solutions, which includes capabilities like Real-Time Liquidity Sharing, Real-Time Multi-Banking, and Real-Time Funding. View original content to download multimedia: SOURCE Citi Singapore Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Astera Labs Announces Third Quarter 2025 Financial Conference Participation
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in financial conferences for the third quarter 2025. Deutsche Bank 2025 Technology Conference on Aug. 28, 2025. Astera Labs' presentation is scheduled for 12:30 pm PT. Citi's 2025 Global TMT Conference on Sept. 4, 2025. Astera Labs' presentation is scheduled for 8:50 am ET. A webcast of each session will be made available on Astera Labs' investor relations website at About Astera Labs Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at IR CONTACT: Leslie
Business Wire
7 hours ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
